In 159 stage I NSGCT cases, 132 were followed by active surveillance after high orchiectomy. Their recurrence-free survival rate (RFS) was compared with 27 cases that received adjuvant treatments, and clinical and pathological parameters were explored to identify significant risk factors of recurrence. Results: Within a median follow-up period of 30.3 months (range: 0.3-65.6 months), 16 (12.1%) of the 132 surveillance cases relapsed at 2.8-51.2 months after high orchiectomy (median: 8.35 months). The 2-year RFS rate was 90%. Eleven (68.8%) cases relapsed within 1 year, and five (31.3%) cases relapsed in 3 years or more. Half (50%) of the recurrences were detected by imaging studies alone, 37.5% by imaging combined with tumor markers, and 12.5% by tumor marker elevation alone. The only significant risk factor of recurrence was the existence of embryonal carcinoma elements in the primary testicular tumor (P = 0.0068). There was no significant difference in RFS between cases with active surveillance and adjuvant treatments. Conclusions: The present report is the first large scale study of clinical stage I NSGCTs in Japan. Active surveillance appears to be an effective treatment option for patients with clinical stage I NSGCTs.
Introduction
Clinical stage I testicular cancer is the most common presentation of testicular cancer (1, 2) . Even with modern staging techniques incorporating computed tomography (CT) and monitoring of serum tumor markers,~30% of patients with clinical stage I non-seminomatous germ cell tumors (NSGCTs) have occult metastatic disease (3, 4) and will have a recurrence if they receive active surveillance after high orchiectomy. However, if retroperitoneal lymph node dissection (RPLND) or adjuvant chemotherapy is administered to patients, many patients will be over-treated, and even if recurrence occurs, almost all cases in the surveillance group can be cured by cisplatinbased chemotherapy (5) . Therefore, active surveillance is generally recommended, particularly for patients thought to have a low recurrence risk. Because of the inaccuracy of clinical staging methods and the risk of metastasis, clinical research focusing on the development of prognostic risk factors remains one of the most important clinical challenges. Here, we report outcomes of active surveillance for clinical stage I NSGCT and an analysis of risk factors for recurrence in a Japanese population.
Methods
A testicular cancer registry program was conducted in 2011 by The Cancer Registration Committee of the Japanese Urological Association (JUA) to collect data of testicular cancer patients diagnosed in 2005 and 2008 from the accredited training institutes for board certification in urology. The survey included details such as age, presenting symptoms, physical examination findings, tumor markers, histopathology, clinical stage, initial treatment and clinical outcomes. The survey did not include the presence of lymphovascular invasion because it is difficult to unify the criteria across all institutions.
Among 1157 patients with testicular tumors registered from 274 institutions nationwide, 729 patients were diagnosed with stage I testicular tumors. Pathological examination of the specimens of high orchiectomy revealed that 160 were clinical stage I NSGCTs. We could not confirm the follow-up data of one patient, and 27 cases received adjuvant treatments. Therefore, we finally analyzed 132 patients with stage I NSGCT followed by active surveillance. The frequency of follow-up investigations was not unified and depended on each institution.
Regarding tumor markers, although recording the human chorionic gonadotropin (HCG) value is encouraged, we excluded it from analysis because in many of the institutions a free HCG-β (ng/ml) measurement kit, which is unsuitable for the International Germ Cell Consensus Classification (6), was used instead of a total HCG (mIU/ml) measurement kit. The normal concentration of α-fetoprotein (AFP) is 20 ng/ml in accordance with JUA Cancer Registration Statistics (1). Lactate dehydrogenase (LDH) was evaluated depending on its normal range for each facility. Pathological details were obtained from reports of each facility.
To predict risk factors, we used the previously published cutoff values of these parameters, i.e., the presence of abnormal serum AFP levels (cutoff: 80 ng/ml) before orchiectomy (7, 8) , pathological tumor (pT) classification (cutoff greater than 1) (9,10), presence of embryonal carcinoma elements (11, 12) , presence of yolk sac elements (10,13) and age (cutoff greater than 30) (13, 14) .
This retrospective study was approved by the Institutional Review Board with all participating sites providing the necessary institutional data sharing agreements prior to initiation.
The variables of the different groups were compared using the chi-squared test or Mann-Whitney U-test. The Kaplan-Meier method was used to estimate recurrence-free survival (RFS) rates that were compared using the log-rank test. RFS was measured from the date of high orchiectomy until the date of diagnosis of recurrence or until the last follow-up. Univariate and multivariate analyses of RFS were performed using the log-rank test or Cox proportional hazards regression models. Significant or marginally significant variables in univariate analyses were chosen for multivariate analysis. Differences among groups were regarded as significant when P < 0.05. These analyses were performed with the Statview version 5.0 statistical software package (SAS Institute, Cary, NC, USA).
Results

Patient characteristics
Median and mean ages of patients were 32.0 and 33.6 years, respectively. Out of 132 patients, 21 patients (15.9%) had a previous history of inguinal or scrotal surgery. One hundred and thirtyone (99.2%) patients presented with a scrotal mass or swelling and 16 (12.1%) patients complained of scrotal pain. One patient presented with gynecomastia. Laterality of the scrotal mass was on the right side in 83 patients (62.9%), the left side in 47 patients (35.6%) and uncertain in 2 patients (1.5%).
AFP was examined in 131 patients (99.2%) and found to be abnormally elevated (>20 ng/ml) in 80 (61.1%) of them (Table 1) . Two patients showed an extremely elevated AFP value of ≥10 Table 2 . Most recurrences (81.3%) were diagnosed within 24 months after initial diagnosis, and there were only three late recurrences (18.7%). The first evidence of recurrence was most commonly identified by imaging alone (50%) or in combination with tumor markers (37.5%; 87.5% overall), and only half of the recurrences had elevated serum markers. The percentage of recurrences detected only by imaging decreased from 54.5% (6 of 11) within the first 12 months to 40% (2 of 5) after 12 months. The percentage of recurrences detected in combination with tumor markers increased from 27.3% (3 of 11) within the first 12 months to 60% (3 of 5) after 12 months. Two recurrences were detected only by increases in tumor markers within 6 months. Out of 16 recurrent patients, all three patients with normal tumor markers at first diagnosis were detected only by imaging and 3 of 13 patients with elevated tumor markers at first diagnosis did not have elevation of tumor markers at recurrence. In 14 patients diagnosed with recurrence by imaging, the recurrent sites were retroperitoneal lymph nodes in all patients, cervical lymph nodes in 2 patients, and the lung and axillary lymph nodes in one patient. There were no cases of recurrence in the chest with normal tumor markers and normal abdominal imaging.
Chemotherapy was carried out in 14 recurrent patients, including bleomycin-etoposide-platinum agent (BEP)/EP in 13 patients: two courses in 3 patients, three courses in 5 patients, four courses in 2 patients, five or six courses in 1 patient, and 1 unknown, and three courses of VIP (vindesine-ifosfamide-platinum agent) in 1 patient.
After median follow-up of 18.5 months from recurrence, no patient has died of the disease and 11 of 16 (68.8%) patients are alive without disease.
Within a median follow-up period of 37.3 months, recurrence occurred in only 1 of 27 (4%) patients who received adjuvant therapy.
The RFS rate is shown in Fig. 1 . The survival rate of patients with active surveillance was compared with that patients who received adjuvant therapy. Out of 159 clinical stage I NSGCT patients, 27 patients received adjuvant therapy after high orchiectomy based on the decision of the physicians in charge. As an adjuvant treatment, chemotherapy (BEP/EP) was administered to 22 patients, radiation therapy (25.2 Gy to para-aortic and ipsilateral iliac fields) was administered to one patient, RPLND was carried out in three patients, and one patient received both chemotherapy and RPLND. There were no significant differences in the characteristics of the two groups except for the histology of the primary testicular tumor. There was also no significant difference in RFS between patients with active surveillance and adjuvant treatments (2-year RFS rates for active surveillance and adjuvant therapy were 90% and 96%, respectively, P = 0.1548). Table 3 shows the predictive factors of tumor recurrence in 132 patients with active surveillance. Age at orchiectomy, preoperative AFP levels and LDH levels were not significantly associated with the risk of recurrence. Furthermore, the pT classification and presence of yolk sac tumor components were not found to be significant in univariate analysis. Only one factor was identified as a significant risk factor for recurrence, the presence of embryonal carcinoma elements. Of 78 patients with embryonal carcinoma elements, 15 (19.2%) had a recurrence, while only one (1.8%) of 55 patients without embryonal carcinoma elements had a recurrence (P = 0.0068).
Assessment of risk factors
Discussion
The majority of patients with NSGCT present with stage I disease. The standard treatment options for patients with clinical stage I disease remain controversial because patients have equally excellent survival with active surveillance, RPLND and primary chemotherapy. Active surveillance is the main option for management of clinical stage I testicular tumors and has been demonstrated as safe and effective in previous studies (15) (16) (17) . However, because the number of cases in individual facilities is small, outcomes of active surveillance of clinical stage I NSGCTs have not been previously evaluated in Japan. The current study was carried out by the JUA to comprehensively aggregate the national registration for testicular cancer. This is the first large scale study of clinical stage I NSGCTs in Japan based on multi-institutional registry data. The present study showed that more than 80% of clinical stage I NSGCTs were followed by active surveillance, which appears to be widely accepted in Japan. A surveillance strategy for stage I NSGCTs provides optimal treatment results with cause-specific survival of 100%. Recurrence occurred in 12.1% of patients and the rest of the patients were cured by high orchiectomy alone.
The recurrence rate (12.1%) in the active surveillance group was relatively shorter than that in previous reports. It cannot be denied that race differences and short follow-up periods have influenced this result. However, considering that many recurrences occur within 2 years, the trend in this follow-up period appears to be reasonable (mean: 30 months). Other causes may be fewer high risk cases because embryonal carcinoma elements were observed in 59.1% of mixed forms in this study (total 61%) and 78% in previous reports. Furthermore, the presence of vascular invasion was not included in our analysis, which has also been indicated as a prognostic factor in previous studies (12, 18) . We cannot deny the possibility of few cases with vascular invasion in our study.
The majority of recurrences occur within the first 2 years after high orchiectomy. Thus, a close follow-up schedule is important during this period. In particular, during the first year, imaging studies are important because half of recurrences are detected by only imaging. Late recurrence from 2 to 5 years after orchiectomy was found in three patients in this study. Only 1-5% of recurrences occur at 5 years or longer after high orchiectomy, and few cases of very late recurrence (>10 years) have been reported (12, 19, 20) . Because the median follow-up period of this study is relatively short compared with that of other studies, a longer observation period is necessary to evaluate the importance of lifelong surveillance.
Although active surveillance is useful to avoid adverse effects of adjuvant therapy and maintain patient quality of life, it is important to determine the risk factors for recurrence and select patients to be offered surveillance. In previous studies, vascular invasion, the presence of embryonal carcinoma in an orchiectomy specimen, absence of yolk sac tumor elements, pT stage, age and AFP level have been identified as risk factors for disease recurrence (5, 8, 10, 13, 14, 18) . However, there have been several negative reports regarding the significance of the AFP level as a risk factor (12) (13) (14) . Vergouwe et al. (13) also reported that AFP is not a valuable predictor for occult metastasis. In this study, the preoperative AFP level was not significantly associated with the risk of recurrence. In contrast, patients with a low AFP level tended to experience tumor recurrence in both univariate and multivariate analyses. We consider that this effect may be caused by understaging of preoperative imaging studies in patients with normal AFP values.
In this study, only the presence of embryonal carcinoma elements was identified as a significant risk factor for recurrence. Even in high resolution CT scans, detection of small volume metastases (<10 mm) is unreliable, and~30% of patients with clinical stage I NSGCTs have occult metastatic disease that is the main cause of recurrence. By RPLND of stage I NSGCTs, Sweeney et al. reported that 32% of clinical stage I embryonal carcinoma-predominant patients had pathological stage II disease. In comparison, only 5.6% of clinical stage I non-embryonal carcinoma-predominant patients had pathological stage II disease. Pathological stage II disease was found to occur statistically more often with embryonal carcinomapredominance than with non-embryonal carcinoma-predominance (21) . Many prior studies have reported the presence of embryonal carcinoma as a risk factor for recurrence, which is in accordance with our results.
In this study, 78 (59.1%) patients had embryonal carcinoma elements. Among them, 15 (19.2%) experienced recurrences. However, if RPLND or adjuvant chemotherapy was limited only to patients with embryonal carcinoma elements,~50% of patients will be overtreated. Therefore, the simple presence of embryonal carcinoma appears to be insufficient to select patients for adjuvant therapy. The presence of vascular invasion has also been indicated as a prognostic factor in previous studies (12, 18) . Furthermore, Divrik et al. (14) reported that the combination of the presence of vascular invasion and percentage of embryonal carcinoma (>50%) yielded a recurrence risk of~75%. Although we had no data about the presence of vascular invasion in this study, additional evaluation including vascular invasion is desirable to identify more specific prognostic factors and reduce the risk of unnecessary adjuvant therapy.
